Evaluating the role of immune-checkpoint inhibitor (ICI) combinations in patients (pts) with unselected “cold” tumors enrolled in early clinical trials (CT)

by on 17 de gener de 2022 with No hi ha comentaris
  • Gadea, O. S. S., Hernando-Calvo, A., Berche, R., Vieito, M., Brana, I., Matos, I., . . . Tabernero, J., Garralda, E. (2021). Evaluating the role of immune-checkpoint inhibitor (ICI) combinations in patients (pts) with unselected “cold” tumors enrolled in early clinical trials (CT). Journal of Clinical Oncology, 39(15). https://doi.org/10.1200/JCO.2021.39.15_suppl.2597 (Meeting abstract)

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *